Declarations of Interest

Expert Group meeting on interim advice for the use of bedaquiline in the treatment of MDR-TB
Declared: insignificant
Erica Lessem
  1. TAG's TB/HIV Project receives funding from the Bill & Melinda Gates Foundation to conduct advocacy to accelerate research and development into new tools to fight TB and TB/HIV coinfection, and to promote universal access to effective tools and services. Activities supported by this funding include TB/HIV Project team operations, participation in meetings with key researchers and policymakers, attendance to scientific conferences, writing publications such as the Pipeline Report which provides an overview of all new drugs, diagnostics and vaccines in the pipeline for TB and other diseases, and coordinating a global TB community advisory board which provides input in the development and roll-out of tools to fight TB.
  2. In addition, TAG's Hepatitis C program received from Janssen Therapeutics/Tibotec Therapeutics $10,000/year in 2011 and 2012 (not for any of my word or the TB/HIV project)

From: Annex 4, Declarations of Interest

Cover of The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis
The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.
Copyright © World Health Organization 2013.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.